Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

albendazole (Rx)Brand and Other Names:Albenza

 
 
 

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

tablet

  • 200mg
more...

Neurocysticercosis (Taenia Solium Tapeworm)

>60 kg: 400 mg PO BID x 8-30 days

<60 kg: 15 mg/kg/day divided BID PO x 8-30 days; not to exceed 800 mg/day 

Hydatid (Echinococcus Tapeworm)

>60 kg: 400 mg PO BID x 28 days, THEN 14 drug-free days x 3 cycles

<60 kg: 15 mg/kg/day divided BID PO, no more than 800 mg/day x 28 days, THEN 14 drug-free days x 3 cycles 

Ancylostoma, Ascariasis, Hookworm, Trichostrongylus

400 mg PO once

Capillariasis

400 mg PO qDay x10 days

Larva Migrans, Cutaneous & Trichuriasis

400 mg PO qDay x 3 days

Larva Migrans, Visceral

400 mg PO BID x 5 days

Enterobius (Pinworm)

400 mg PO once, repeat in 2 weeks

Fluke (Clonorchis Sinensis)

10 mg/kg PO qDay x7 days

Gnathostomiasis, Microsporidiosis

400 mg BID x 21 days

Administration

Take with food

Monitor: CBC, LFTs

Dosage Forms & Strengths

tablet

  • 200mg
more...

Neurocysticercosis (Taenia Solium Tapeworm)

<60 kg: 15 mg/kg/day divided BID PO x 8-30 day; no more than 800 mg/day (maximum total daily dose, 800 mg) 

>60 kg: 400 mg BID x 8-30 day

Hydatid (Echinococcus Tapeworm)

<60 kg: 15 mg/kg/day divided BID PO, no more than 800 mg/day x 28 days, THEN 14 drug-free days x 3 cycles 

>60 kg: 400 mg PO BID x 28 days, THEN 14 drug-free days x 3 cycles

Ancylostoma, Ascariasis, Hookworm, Trichostrongylus

400 mg PO x1 day

Capillariasis

400 mg PO qDay x10 days

Larva Migrans, Cutaneous & Trichuriasis

400 mg PO qDay x 3 days

Larva Migrans, Visceral

400 mg PO BID x 5 days

Enterobius (Pinworm)

400 mg PO x 1, repeat in 2 weeks

Other Information

Administration

  • Take with food
  • If unable to swallow, may crush tablet & drink with water

Monitor

  • CBC, LFTs
Next

Interactions

Interaction Checker

albendazole and

No Results

     
     activity indicator 
    No Interactions Found
    Interactions Found

    Contraindicated

      Serious - Use Alternative

        Significant - Monitor Closely

          Minor

            Sort by :  
             activity indicator 
            Previous
            Next

            Adverse Effects

            >10%

            Headache

            • Neurocysticercosis (11%)
            • Hydatid disease (1.3%)

            Abnormal LFT

            • Hydatid disease (15.6%)
            • Neurocysticercosis (<1%)

            1-10%

            Abdominal pain

            • Hydatid disease (6%)

            Nausea/vomiting

            • Hydatid disease (3.7%)
            • Neurocysticercosis (6.2%)

            Dizziness/vertigo

            • Hydatid disease (1.2%)
            • Neurocysticercosis (<1%)

            Increased intracranial pressure

            • Neurocysticercosis (1%)

            Meningeal signs

            • Neurocysticercosis (1%)

            Alopecia (reversible)

            • Hydatid disease (1.6%)
            • Neurocysticercosis (<1%)

            Fever

            • Hydatid disease (1%)

            <1% (selected)

            Rash

            Urticaria

            Agranulocytosis

            Aplastic anemia

            Bone marrow suppression

            Granulocytopenia

            Pancytopenia

            Thrombocytopenia

            Hepatitis

            Acute liver failure

            Acute renal failure

            Previous
            Next

            Warnings

            Contraindications

            Hypersensitivity to albendazole or benzimidazoles

            Cautions

            Monitor theophylline levels if used concomitantly

            Potential for bone marrow suppression, aplastic anemia & agranulocytosis; monitor blood counts in all patients at the beginning of each 28-day cycle of therapy, and every 2 weeks while on therapy; discontinue therapy if clinically significant changes in blood counts occur

            Pre-existing neurocysticercosis may be uncovered in patients treated w/ albendazole for other conditions, apparent by neurological symptoms (eg, seizures, increased intracranial pressure, focal signs); promptly treat w/ corticosteroid & anticonvulsant therapy

            Obtain pregnancy test in women of reproductive potential prior to therapy and avoid usage in pregnant women except in clinical circumstances where no alternative management is appropriate; discontinue therapy if pregnancy occurs and apprise patient of potential hazard to fetus

            Risk of retinal damage in retinal cysticercosis; cases of retinal involvement reported; examine patient for presence of retinal lesions before initiating therapy for neurocysticercosis

            Reversible elevations of liver enzymes may occur; monitor liver enzymes before start of each treatment cycle and at least every 2 weeks while on therapy and discontinue if clinically significant elevations occur; patients with abnormal LFTs and hepatic echinococcosis are at increased risk of hepatotoxicity; discontinue therapy if LFT elevations >2 times upper limit of normal; may consider restarting treatment when LFT values return to pretreatment levels

            Previous
            Next

            Pregnancy & Lactation

            Pregnancy Category: C

            Lactation: unknown, use caution

            Pregnancy Categories

            A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

            B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

            C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

            D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

            X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

            NA:Information not available.

            more...
            Previous
            Next

            Pharmacology

            Mechanism of Action

            Causes degeneration of cytoplasmic microtubule in intestinal and tegmental cells of intestinal helminths

            Pharmacokinetics

            Absorption: <5%; may increase up to 4-5 times with a fatty meal

            Distribution: Well inside hydatid cysts & CSF

            Protein Bound: 70%

            Metabolism: Hepatic; extensive first-pass effect; pathways include rapid sulfoxidation (major), hydrolysis, & oxidation

            Half-life: 8-12 hr

            Peak Plasma Time: 2-5 hr

            Excretion: urine (<1% as active metabolite); feces

            Previous
            Next

            Images

            Previous
            Next

            Formulary

            FormularyPatient Discounts

            To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

            Adding plans allows you to:

            • View the formulary and any restrictions for each plan.
            • Manage and view all your plans together – even plans in different states.
            • Compare formulary status to other drugs in the same class.
            • Access your plan list on any device – mobile or desktop.

            The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

            Tier Description
            1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
            2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
            3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
            4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            NC NOT COVERED – Drugs that are not covered by the plan.
            Code Definition
            PA Prior Authorization
            Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
            QL Quantity Limits
            Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
            ST Step Therapy
            Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
            OR Other Restrictions
            Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
            Add or Remove Plans
            Plans for
            Select State:
            Non-Medicare PlansMedicare Plans

            Select a box to add or remove a plan.

            Select a class to view formulary status for similar drugs

            Additional Offers
            Email to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Email Forms to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Previous
             
             
             
            All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.